New study tracks Larotrectinib's Real-World impact on rare TRK fusion cancers
NCT ID NCT04945330
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 37 times
Summary
This study follows 100 adults and children with advanced or recurrent TRK fusion cancer who are taking larotrectinib as part of their routine care. Researchers will collect information from medical records and interviews to learn about the drug's safety and how well it controls tumor growth. The goal is to understand real-world outcomes, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR RECURRENT SOLID TUMOR HARBORING AN NTRK GENE FUSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many locations
RECRUITINGMultiple Locations, Japan
Conditions
Explore the condition pages connected to this study.